Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: JFitnich who wrote (823)	4/20/1999 7:59:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 1073

Messrs. Tisch now own over 10% of the company, having grabbed a hunk on 3/31 and smaller chunks over the two weeks prior to that (731K new shares total over that period). Big money investors, not accustomed to passively sitting back and twiddling thumbs. from the new 10-K...... The following table lists the Company's most advanced programs and the current status of these programs. DISORDER TARGET MECHANISM PROGRAM STATUS COMMERCIAL RIGHTS <S> <C> <C> <C> Anxiety GABA NGD 91-2 Phase I Pfizer (Neurogen royalty) (1) NGD 91-3 pre- clinical development (2) Insomnia GABA NGD 96-1 Phase I human Pfizer (Neurogen royalty) clinical trials (1) NGD 96-2 pre-clinical development (2) Dementia, cognition deficits GABA NGD 97-1 Phase I human Pfizer (Neurogen royalty) clinical trials (1) Depression and stress-related CRF1 NGD 98-1 pre-clinical Neurogen disorders development (2) Obesity and other eating disorders Neuropeptide Y Evaluation of new pre-clinical Pfizer (Neurogen royalty, candidates (2) following manufacturing and profit safety test of NGD 95-1 in sharing options) Phase I clinical trials (1) Schizophrenia Dopamine Evaluation of new Schering-Plough (Neurogen royalty candidates following and manufacturing option) Phase I (1) trials of NGD 94-4 and NGD 94-1 Inflammatory disorders, C5a Leads identified (3) Neurogen rheumatoid arthritis Depression NK Leads Identified (3) Neurogen Asthma Bradykinin Leads identified (3) Neurogen Type II diabetes, obesity GLP1 - like Leads identified (3) Neurogen Depression Neuropeptide Y Leads identified (3) Neurogen Anxiety in companion animals (4) GABA receptor subtypes Leads identified (3) Pfizer (Neurogen royalty) Dementia in companion animals (4) GABA receptor subtypes Leads identified (3) Pfizer (Neurogen royalty)

To: JFitnich who wrote (823)	4/20/1999 8:38:00 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 1073

Thanks JF. As Rick posted, NRGN selected in 98 their lead CRFr antagonist candidate for late stage pre-clinical development. However, I had detected several patents and patent applications on CRFr antagonist and their application (US, EU and worldwide). So, I was interested did any of this applicant actually pushed their programs/candidates forward. As Dr. Tracy stated, neuroscience show growing interest for this approach/target as depression/anxiety therapy, and it will be, imo, hot issue in near future. <<Maybe Dr. Tracy would care to shed some light.>> I hope to make peace with him, so I wish that he respond. Miljenko